Lubrizol's Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona
Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona
Lubrizol Launches Carbopol® Polymers for Nutraceuticals with New EU Food Grade Approval
CLEVELAND--(BUSINESS WIRE)--The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows Welton to use the Apisolex excipient worldwide to develop and commercialize a novel formulation of SN-38 to treat colorectal and associated gastro-intestinal cancers.
Lubrizol Showcases Plant-based Iron-Fortified Gummies
Lubrizol’s Apisolex Technology Voted Grand Winner of the 7th Annual Medicine Maker Innovation Awards
Taking production of your sterile drug product from clinical to commercial scale is a ncomplicated and challenging process with many factors to consider. This nis particularly true when it comes to the scale-up of aseptic nmanufacturing processes, which are increasingly common in the npharmaceutical industry.
Throughout modern history, humans have been battling infectious diseases. These diseases pose significant global health issues, and the introduction of prophylactic vaccination has been critical in combatting them. The COVID-19 pandemic, caused by the novel SARS-CoV-2 coronavirus, highlights the need for safe and effective vaccines against new pathogens. Dozens of companies and research groups are working on vaccines for COVID-19 as of April 2020.
BARCELONA, Spain, Oct. 28, 2020 /PRNewswire/ -- Lubrizol Life Science Health (LLS Health) launches ASTAGILE™ microcapsules, its new sustainable, organic-certified, astaxanthin (Haematococcus pluvialis), microencapsulated with spirulina. The two ingredients have been uniquely combined in a patent-pending product designed to promote mental agility and support healthy ageing for young and senior adults.